Damora Therapeutics (DMRA) Net Income Growth (3y) (2022 - 2026)

Damora Therapeutics (DMRA) Net Income Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Oculis Holding AG 66,861.65 Bn 66,861.36 Bn - 9.16%
2 Nanobiotix 1,910.87 Bn 1,910.81 Bn - -
3 Akari Therapeutics 989.71 Bn 989.71 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.90 Bn 61.14 Bn 3.31 Bn -3.84%
7 Belite Bio 62.74 Bn 62.74 Bn - -
8 Argenx Se 55.83 Bn 50.65 Bn 1.41 Bn 79.26%
9 Revolution Medicines 37.46 Bn 37.46 Bn - -
10 Damora Therapeutics 1.02 Bn 817.66 Mn - -23.02%

Historic Data

Download Data
DateValue
Mar 31, 2026 -23.02%
Dec 31, 2025 -143.24%
Sep 30, 2025 38.93%
Jun 30, 2025 41.58%
Mar 31, 2025 47.27%
Dec 31, 2024 20.82%
Sep 30, 2024 36.27%
Jun 30, 2024 31.03%
Mar 31, 2024 33.88%
Dec 31, 2023 29.00%
Sep 30, 2023 7.36%
Jun 30, 2023 -19.00%
Mar 31, 2023 -36.55%
Dec 31, 2022 -36.64%
Sep 30, 2022 -69.48%